ISO · Isoplexis Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|
| Revenue | - | $4.48M | $4.29M | $4.91M | - | $3.28M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | $2.26M | $2.28M | $2.56M | - | $1.76M |
| R&D | - | $4.17M | $5.50M | $7.13M | - | $4.70M |
| SG&A | - | $8.78M | $8.45M | $11.48M | - | $7.11M |
| Total Operating Expenses | - | $19.23M | $20.64M | $15.13M | - | $8.01M |
| D&A | - | $1.60M | $1.10M | $308.0K | - | - |
| Operating Income | - | ($16.97M) | ($18.35M) | ($28.10M) | - | ($19.90M) |
| Interest Expense | - | $1.49M | $1.21M | $986.0K | - | $1.07M |
| Income Tax | - | - | - | - | - | - |
| Net Income | - | ($18.45M) | ($25.61M) | ($28.73M) | - | ($5.04M) |
| EPS - Basic | - | ($0.47) | ($11.10) | ($0.74) | - | ($10.66) |
| EPS - Diluted | - | ($0.47) | ($11.10) | ($0.74) | - | ($10.66) |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.47M | $53.13M | $71.61M | $97.61M | $126.57M | $106.64M |
| Accounts Receivable | $4.50M | $4.57M | $3.48M | $3.94M | $4.10M | $3.49M |
| Inventory | $27.52M | $38.25M | $38.99M | $34.50M | $24.30M | $20.23M |
| Accounts Payable | $2.78M | $4.03M | $4.25M | $10.24M | $4.84M | $5.91M |
| Current Assets | $71.86M | $97.62M | $116.22M | $139.29M | $158.44M | $72.08M |
| Total Assets | $109.07M | $134.85M | $152.97M | $176.11M | $187.47M | $123.61M |
| Current Liabilities | $17.71M | $11.22M | $11.39M | $17.91M | $13.58M | $4.62M |
| Long-term Debt | $46.35M | $46.05M | $45.90M | $38.90M | $31.65M | $31.77M |
| Total Liabilities | $67.80M | $61.35M | $62.39M | $61.41M | $45.23M | $31.40M |
| Stockholders' Equity | $41.27M | $73.50M | $90.58M | $114.70M | $142.25M | ($38.60M) |
| Retained Earnings | ($239.97M) | ($206.76M) | ($188.30M) | ($162.70M) | ($133.97M) | ($52.40M) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($14.42M) | - | - |
| Investing Cash Flow | - | - | - | ($825.0K) | - | - |
| Financing Cash Flow | - | - | - | $10.01M | - | - |
| CapEx | - | - | - | $4.39M | - | - |
| Free Cash Flow | - | - | - | ($18.82M) | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | 50.3% | 53.3% | 52.0% | - | 53.7% |
| Operating margin | - | -378.5% | -427.9% | -572.1% | - | -606.9% |
| EBITDA margin | - | -342.8% | -402.3% | -565.9% | - | - |
| Net margin | - | -411.6% | -597.0% | -584.9% | - | -153.9% |
| Free cash flow margin | - | - | - | -383.1% | - | - |
| FCF / Net income | - | - | - | 0.66 | - | - |
| R&D / Revenue | - | 93.0% | 128.1% | 145.2% | - | 143.3% |
| SG&A / Revenue | - | 195.9% | 196.9% | 233.7% | - | 216.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | - | -13.7% | -16.7% | -16.3% | - | -4.1% |
| Return on equity | - | -25.1% | -28.3% | -25.0% | - | 13.1% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.06 | 8.70 | 10.20 | 7.78 | 11.67 | 15.59 |
| Quick ratio | 2.50 | 5.29 | 6.78 | 5.85 | 9.88 | 11.22 |
| Cash ratio | 2.12 | 4.74 | 6.29 | 5.45 | 9.32 | 23.07 |
| Leverage | ||||||
| Debt / Equity | 1.12 | 0.63 | 0.51 | 0.34 | 0.22 | -0.82 |
| Debt / Assets | 0.43 | 0.34 | 0.30 | 0.22 | 0.17 | 0.26 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -11.4x | -15.2x | -28.5x | - | -18.7x |
| Equity multiplier | 2.64 | 1.83 | 1.69 | 1.54 | 1.32 | -3.20 |
| Liabilities / Assets | 0.62 | 0.45 | 0.41 | 0.35 | 0.24 | 0.25 |
| Efficiency | ||||||
| Asset turnover | - | 0.03 | 0.03 | 0.03 | - | 0.03 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | 372d | 296d | 293d | - | 389d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | 36.7% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | 28.2% | - | - | - | - |
| Operating income growth (YoY) | - | 14.7% | - | - | - | - |
| Net income growth (YoY) | - | -265.8% | - | - | - | - |
| EPS growth (YoY) | - | 95.6% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -71.0% | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$34.52M totalProduct$16.20M · 46.9%
Product Instruments$11.42M · 33.1%
Product Consumables$4.78M · 13.9%
Service$1.06M · 3.1%
Service Extended Service Warranty$681.0K · 2.0%
Service Other$376.0K · 1.1%
Geographic
$17.26M totalAmericas$12.80M · 74.2%
Europe$2.29M · 13.3%
CN$1.31M · 7.6%
Asia Pacific$860.0K · 5.0%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing IsoPlexis Corp against the 5 most active filers in the same SIC group.